ORIC Pharmaceuticals, Inc. ORIC
8.95 USD +0.04 (+0.45%)
Nov 11, 2026, 12:39 PM EST
8.84 Day range 9.00
7.23 52-week range 14.68
- YTD
- +9.41%
- 1 year
- -30.51%
News
globenewswire.com ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
benzinga.com BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
benzinga.com Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14 Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18 Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
benzinga.com ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
benzinga.com Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for ACI, ORIC, JPM, SHOP, META and U; KTB upgraded to Buy. Domino’s target was cut.
benzinga.com JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26 JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.
benzinga.com ORIC Pharmaceuticals Announces Agreement With Cancer Research UK To Advance Potential CIP2A-Targeted Therapy Into Clinical Development ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable targetCancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies…- benzinga.com Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26 Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.
benzinga.com BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26 BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.- benzinga.com HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27 HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
- benzinga.com ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market session. The market value of their outstanding shares is at $2.6 million. China Pharma Holding (AMEX:CPHI)…
- benzinga.com ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQA Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateroneEntered into a clinical trial collaboration and supply agreement with Bayer to provide…
benzinga.com Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.- benzinga.com HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
- benzinga.com Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16 Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.
- benzinga.com ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeting On Potential Of Rinzimetostat For Prostate Cancer Treatment ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com What's Behind The Drop In Oric Pharmaceuticals Stock Today? Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients…- benzinga.com Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $17 Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $20 to $17.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.
benzinga.com Market-Moving News for April 1st NKE: -10% | Nike shares are trading lower after the company reported Q3 financial results. Also, the company issued Q4 sales guidance below estimates. ORIC: -36% | Oric Pharmaceuticals shares are…
benzinga.com Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 results and issuing positive guidance for Q1 and FY27.
benzinga.com ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On? ORIC Pharmaceuticals stock rose after reporting positive cancer drug data and advancing to a Phase 3 trial, before falling sharply in after-hours trading.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com ORIC Pharma Announces Efficacy And Safety Data From Phase 1b Trial Of Once Daily Rinzimetostat In Combination With Darolutamide In Patients With mCRPC Who Were Previously Treated With Abiraterone Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026At…
- benzinga.com ORIC Pharmaceuticals To Share Combination Dose Optimization Data From Phase 1b Study Of Rinzimetostat In Participants With Metastatic Castration Resistant Prostate Cancer ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it will report…
- benzinga.com HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading…
benzinga.com Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.
benzinga.com Methanex Posts Downbeat Q4 Results, Joins Gap, Nutex Health, Owlet And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures lower, Dow down 100 points. Methanex (MEOH) shares fall 8.7% after reporting quarterly losses and missed sales estimates.
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In December 
benzinga.com This Helmerich and Payne Analyst Is No Longer Bearish; Here Are Top 3 Upgrades For Friday 
benzinga.com This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
benzinga.com This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday 
benzinga.com This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday 
benzinga.com This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
benzinga.com Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results 
benzinga.com Veeva Systems, e.l.f. Beauty, C3.ai, BRP And Other Big Stocks Moving Higher On Thursday 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.